252 related articles for article (PubMed ID: 19230928)
1. Tumor associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes.
Brandau S
J Urol; 2009 Apr; 181(4):1532-3. PubMed ID: 19230928
[No Abstract] [Full Text] [Related]
2. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
[TBL] [Abstract][Full Text] [Related]
3. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
Gaya JM; Palou J; Algaba F; Arce J; Rodríguez-Faba O; Villavicencio H
Can J Urol; 2010 Oct; 17(5):5370-6. PubMed ID: 20974029
[TBL] [Abstract][Full Text] [Related]
4. Re: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.
Klotz L
J Urol; 2000 Nov; 164(5):1666. PubMed ID: 11025741
[No Abstract] [Full Text] [Related]
5. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
Rosevear HM; Lightfoot AJ; Birusingh KK; Maymí JL; Nepple KG; O'Donnell MA;
J Urol; 2011 Sep; 186(3):817-23. PubMed ID: 21788050
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guérin immunotherapy.
Kim SJ; You D; Jeong IG; Song C; Hong B; Kim CS; Ahn H; Hong JH
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2131-2140. PubMed ID: 31227894
[TBL] [Abstract][Full Text] [Related]
7. Prostatorectal fistula following intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the urinary bladder.
Enatsu N; Ota T; Ochi A
Int J Urol; 2010 Sep; 17(9):822-3. PubMed ID: 20727055
[No Abstract] [Full Text] [Related]
8. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
de Reijke TM
Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
[No Abstract] [Full Text] [Related]
9. Bacillus Calmette-Guerin therapy for bladder carcinoma in situ: use in a clinical setting.
Skaugen P
Urol Nurs; 1997 Jun; 17(2):69-71. PubMed ID: 9239141
[No Abstract] [Full Text] [Related]
10. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
11. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
[TBL] [Abstract][Full Text] [Related]
12. Stromal invasion of the prostate following a complete response to bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the ureter and the bladder.
Hara I; Yao A; Muramaki M; Hikosaka S; Yamada Y; Kawabata G; Kamidono S
Int J Urol; 2004 Apr; 11(4):250-2. PubMed ID: 15028107
[TBL] [Abstract][Full Text] [Related]
13. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy.
Herr HW
Urology; 2007 Jul; 70(1):65-8. PubMed ID: 17656210
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Chen F; Zhang G; Cao Y; Payne R; See WA
J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
[TBL] [Abstract][Full Text] [Related]
15. Is maintenance Bacillus Calmette-Guérin really necessary?
Herr HW
Eur Urol; 2008 Nov; 54(5):971-3. PubMed ID: 18585842
[No Abstract] [Full Text] [Related]
16. Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
Mehraban D; Esfahani F
J Urol; 2005 Sep; 174(3):1151; author reply 1151. PubMed ID: 16094088
[No Abstract] [Full Text] [Related]
17. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
18. Re: Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer s. P. Lerner, C. M. Tangen, H. Sucharew, D. Wood and E. D. Crawford J Urol 2007; 177: 1727-1731.
Lamm DL
J Urol; 2008 Feb; 179(2):788. PubMed ID: 18082825
[No Abstract] [Full Text] [Related]
19. [Carcinoma in situ in bladder and urethra among renal transplanted patient: failure of BCG therapy].
Tillou X; Raynal G; Limani K; Saint F; Petit J
Prog Urol; 2008 Dec; 18(13):1097-9. PubMed ID: 19041819
[TBL] [Abstract][Full Text] [Related]
20. T1G3 bladder cancer and Bacillus Calmette-Guérin: tell me something we don't know.
Yates DR
Eur Urol; 2015 Jan; 67(1):83-84. PubMed ID: 25109573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
